Mark A. Velleca - 13 Jul 2021 Form 4 Insider Report for G1 Therapeutics, Inc.

Role
Director
Signature
/s/ James Stillman Hanson, attorney-in-fact
Issuer symbol
N/A
Transactions as of
13 Jul 2021
Net transactions value
-$558,558
Form type
4
Filing time
15 Jul 2021, 16:01:39 UTC
Previous filing
17 Jun 2021
Next filing
11 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $3,900 +10,000 +16% $0.3900* 71,000 13 Jul 2021 Direct
transaction GTHX Common Stock Sale $194,536 -10,000 -14% $19.45* 61,000 13 Jul 2021 Direct F1, F2
transaction GTHX Common Stock Options Exercise $3,900 +10,000 +16% $0.3900* 71,000 14 Jul 2021 Direct
transaction GTHX Common Stock Sale $190,824 -10,000 -14% $19.08* 61,000 14 Jul 2021 Direct F1, F3
transaction GTHX Common Stock Options Exercise $3,900 +10,000 +16% $0.3900* 71,000 15 Jul 2021 Direct
transaction GTHX Common Stock Sale $184,898 -10,000 -14% $18.49* 61,000 15 Jul 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10,000 -3.9% $0.000000 247,286 13 Jul 2021 Common Stock 10,000 $0.3900 Direct F5
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10,000 -4% $0.000000 237,286 14 Jul 2021 Common Stock 10,000 $0.3900 Direct F5
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10,000 -4.2% $0.000000 227,286 15 Jul 2021 Common Stock 10,000 $0.3900 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $19.25 and a high of $19.85. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3 The price represents the weighted average price with a low of $18.90 and a high of $19.22. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
F4 The price represents the weighted average price with a low of $18.29 and a high of $18.64. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
F5 All shares underlying this option have vested.